Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib vs Ustekinumab in Moderate-to-Severe Plaque Psoriasis
NCT07116967Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Primary completion
- Jan 2031
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of deucravacitinib in plaque psoriasis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Composite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularization at 5 years. Started Sep 2025; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07116967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07116967.